Answers are grounded in this paper and cite their sources.
Reports on longitudinal associations of polypharmacy and frailty with cardiovascular events and mortality in middle-aged adults, highlighting potential interactions between both conditions.
Studies of the associations of polypharmacy and frailty with adverse health outcomes in middle-aged adults are limited. Furthermore, a potentially stronger association of polypharmacy with adverse health outcomes in frail than in non-frail adults is of interest.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: